Abstract

Human induced pluripotent stem cells (hiPSCs) have enormous potential for the treatment of inherited and acquired disorders. Recently, antigen-specific T lymphocytes derived from hiPSCs have been reported. However, T lymphocyte populations with broad T cell receptor (TCR) diversity have not been generated. We report that hiPSCs derived from skin biopsy are capable of producing T lymphocyte populations with a broad TCR repertoire. In vitro T cell differentiation follows a similar developmental program as observed in vivo, indicated by sequential expression of CD7, intracellular CD3 and surface CD3. The γδ TCR locus is rearranged first and is followed by rearrangement of the αβ locus. Both γδ and αβ T cells display a diverse TCR repertoire. Upon activation, the cells express CD25, CD69, cytokines (TNF-α, IFN-γ, IL-2) and cytolytic proteins (Perforin and Granzyme-B). These results suggest that most, if not all, mechanisms required to generate functional T cells with a broad TCR repertoire are intact in our in vitro differentiation protocol. These data provide a foundation for production of patient-specific T cells for the treatment of acquired or inherited immune disorders and for cancer immunotherapy.

Highlights

  • Mouse induced pluripotent stem cells were first created by overexpression of Oct4, Sox2, Klf4 and c-Myc in somatic cells [1]

  • We established a 2-step method to expand hematopoietic zone (HZ). human induced pluripotent stem cells (iPSCs) (hiPSCs) were cultured on OP9 for 11 days, and a sample of these cells was analyzed by FACS (Day 11 cells)

  • We affinity-purified CD34+ cells generated from hiPSCs and control human ESCs (hESCs) at Day18 under these conditions and analyzed the cells in colony forming cell (CFC) assays

Read more

Summary

Introduction

Mouse induced pluripotent stem cells (iPSCs) were first created by overexpression of Oct, Sox, Klf and c-Myc in somatic cells [1]. Mouse and human iPSCs have similar morphologies, and share two important features of embryonic stem cells (ESCs), pluripotency and selfrenewal The combination of these two properties plus the potential to grow unlimited numbers of cells that are isogenic to the somatic cell donor makes hiPSCs unprecedented in possible medical applications. Mouse iPSCs (miPSCs) derived from the humanized, sickle mice were corrected by gene replacement and differentiated into Sca-1 positive, c-Kit positive and SSEA-1 negative hematopoietic stem/progenitor cells (HSC/HPC). These cells were transplanted into humanized, sickle mouse recipients, and all red cell indices were restored to the normal range. These results demonstrated that iPSC based gene/cell therapy can be used to cure an inherited disorder

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call